[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@iHooghvorst Avatar @iHooghvorst Linden

Linden posts on X about $abcl, eli lilly, $abbv, collab the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #

Social category influence stocks

Social topic influence $abcl, eli lilly, $abbv, collab, $abcls, the early, $snys

Top assets mentioned Eli Lilly and Company (LLY) AbbVie Inc (ABBV)

Top Social Posts #

Top posts by engagements in the last XX hours

"Carl Hansen vision for Canadas health sector $ABCL. Great read. Thanks @Algo_Stoney for finding it"
X Link @iHooghvorst 2025-09-02T14:21Z 3351 followers, 10.8K engagements

"@Jare92365776 Good finding 🫶. Its good to see progress on different partnerships through different routes papers published with gilead eli Lilly continuation abbvie new collab on tce spce and now this w vikings"
X Link @iHooghvorst 2025-10-13T06:09Z 3352 followers, XXX engagements

"Hot take on $ABCL's XXX after the disappointing XX% placebo-adjusted remission rate for Sanofi's amlitelimab in its Phase X COAST-1 trial. Both molecules target the early OX40L checkpoint for inflammation in AtD. $SNY's results are encouraging in terms of MoA validation but weren't quite up to the expectations set by Dupixent (27% remission at Week XX in CHRONOS). AbCelleras molecule has an engineered Fc that provides an extended half-life alongside Fc silencing. This could translate to less frequent dosing and more consistent blockade of OX40L potentially resulting in improved remission"
X Link @iHooghvorst 2025-10-22T11:47Z 3354 followers, 5317 engagements